Skip to main content
Erschienen in: Pathology & Oncology Research 2/2020

06.01.2019 | Original Article

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma

verfasst von: Z. Burián, A. Ladányi, T. Barbai, V. Piurkó, T. Garay, E. Rásó, József Tímár

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Zinc as an essential trace metal is a ubiquitous component of various molecules of the cell. Studies indicated that it may modulate functions of various cancer cell types, and can even inhibit metastasis formation in experimental models. In melanoma, zinc was shown to affect melanin production and to induce apoptosis. Using human melanoma cell lines, we have tested the effects of ZnSO4 on cell proliferation, survival, migration as well as in vivo on experimental liver colony formation. We have found that ZnSO4 has antiproliferative and proapoptotic effects in vitro. In SCID mice intraperitoneal administration of ZnSO4 specifically inhibited liver colony formation without affecting primary tumor growth. To reveal the molecular mechanisms of action of zinc in human melanoma, we have tested mRNA expression of zinc finger transcription factors and found a strong inhibitory effect on HIF1α, as compared to WT1 whereas HIF2α and MTF1 expression was unaffected. Immunohistochemical detection of HIF1α protein in liver metastases confirmed its decreased nuclear expression after in vivo ZnSO4 treatment. These data indicate that in human melanoma zinc administration may have an antimetastatic effect due to a selective downregulation of HIF1α.
Literatur
1.
Zurück zum Zitat Vallee BL, Falchuk KH (1993) The biochemical basis of zinc physiology. Phys Rev 73:79–118 Vallee BL, Falchuk KH (1993) The biochemical basis of zinc physiology. Phys Rev 73:79–118
2.
Zurück zum Zitat Grattan BJ, Freake HC (2012) Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients 4:648–675CrossRef Grattan BJ, Freake HC (2012) Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients 4:648–675CrossRef
3.
Zurück zum Zitat Intsuka S, Araki S (1978) Plasma copper and zinc levels in patients with malignant tumors of digestive organs: clinical evaluation of the cu/Zn ratio. Cancer 42:626–631CrossRef Intsuka S, Araki S (1978) Plasma copper and zinc levels in patients with malignant tumors of digestive organs: clinical evaluation of the cu/Zn ratio. Cancer 42:626–631CrossRef
4.
Zurück zum Zitat Hisaki T, Furumoto T, Nozaka K, Koga S (1988) Serum zinc and copper changes after gastrectomy in aged patients with gastric cancer. Jpn J Sur 18:158–163CrossRef Hisaki T, Furumoto T, Nozaka K, Koga S (1988) Serum zinc and copper changes after gastrectomy in aged patients with gastric cancer. Jpn J Sur 18:158–163CrossRef
5.
Zurück zum Zitat Prasad AS, Beck FW, Doerr TD, Shamsa FH, Mathog RH (1998) Nutritional and zinc status of head and neck cancer patients: an interpretive review. Am Coll Nutr 17:409–418CrossRef Prasad AS, Beck FW, Doerr TD, Shamsa FH, Mathog RH (1998) Nutritional and zinc status of head and neck cancer patients: an interpretive review. Am Coll Nutr 17:409–418CrossRef
6.
Zurück zum Zitat Yucel I, Arpaci F, Ozet A, Berk O (1994) Serum copper and zinc levels and copper/zinc ratio in patients with breast cancer. Biol Trace Elem Res 40:31–38CrossRef Yucel I, Arpaci F, Ozet A, Berk O (1994) Serum copper and zinc levels and copper/zinc ratio in patients with breast cancer. Biol Trace Elem Res 40:31–38CrossRef
7.
Zurück zum Zitat Igic PG, Lee E, Harper W, Roach KW (2012) Toxic effects associated with consumption of zinc. Mayo Clin Proc 77:713–716CrossRef Igic PG, Lee E, Harper W, Roach KW (2012) Toxic effects associated with consumption of zinc. Mayo Clin Proc 77:713–716CrossRef
8.
9.
Zurück zum Zitat Timar J, Raso R, Paku S, Kopper L (1998) Oral administration of a trace element preparation and zinc inhibit liver metastasis of 3LL-HH murine tumor cells. Int J Mol Med 2:105–113PubMed Timar J, Raso R, Paku S, Kopper L (1998) Oral administration of a trace element preparation and zinc inhibit liver metastasis of 3LL-HH murine tumor cells. Int J Mol Med 2:105–113PubMed
10.
Zurück zum Zitat Dubi N, Gheber L, Fisgman D, Sekler I, Hershfinkel M (2008) Extracellular zinc and zinc-citrate, acting through a putative zinc-sensing receptor, regulate growth and survival of prostate cancer cells. Carcinogenesis 29:1692–1702CrossRef Dubi N, Gheber L, Fisgman D, Sekler I, Hershfinkel M (2008) Extracellular zinc and zinc-citrate, acting through a putative zinc-sensing receptor, regulate growth and survival of prostate cancer cells. Carcinogenesis 29:1692–1702CrossRef
11.
Zurück zum Zitat Hwang JJ, Kim HN, Kim J, Cho DH, Kim MJ, Kim YS, Kim Y, Park SJ, Koh JY (2010) Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals 23(6):997–1013CrossRef Hwang JJ, Kim HN, Kim J, Cho DH, Kim MJ, Kim YS, Kim Y, Park SJ, Koh JY (2010) Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals 23(6):997–1013CrossRef
12.
Zurück zum Zitat Yamada H, Suzuki K, Koizumi S (2007) Gene expression profile in human cells exposed to zinc. J Toxicol Sci 32:193–196CrossRef Yamada H, Suzuki K, Koizumi S (2007) Gene expression profile in human cells exposed to zinc. J Toxicol Sci 32:193–196CrossRef
13.
Zurück zum Zitat Kindermann B, Döring F, Pfaffl M, Daniel H (2004) Identification of genes responsive to intracellular zinc depletion in the human colon adenocarcinoma cell line HT-29. J Nutr 134:57–62CrossRef Kindermann B, Döring F, Pfaffl M, Daniel H (2004) Identification of genes responsive to intracellular zinc depletion in the human colon adenocarcinoma cell line HT-29. J Nutr 134:57–62CrossRef
14.
Zurück zum Zitat Schadendorf D, vanAkkoi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A et al (2018) Melanoma. Lancet 392:971–984CrossRef Schadendorf D, vanAkkoi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A et al (2018) Melanoma. Lancet 392:971–984CrossRef
15.
Zurück zum Zitat Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL Jr. (2003) Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 16:273–279CrossRef Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL Jr. (2003) Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 16:273–279CrossRef
16.
Zurück zum Zitat Ladányi A, Tímár J, Paku S, Molnár G, Lapis K (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46:456–461CrossRef Ladányi A, Tímár J, Paku S, Molnár G, Lapis K (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46:456–461CrossRef
17.
Zurück zum Zitat Timár J, Rásó E, Honn KV, Hagmann W (1999) 12-lipoxygenase expression in human melanoma cell lines. Adv Exp Med Biol 469:617–622CrossRef Timár J, Rásó E, Honn KV, Hagmann W (1999) 12-lipoxygenase expression in human melanoma cell lines. Adv Exp Med Biol 469:617–622CrossRef
18.
Zurück zum Zitat Garay, T., E. Juhasz, E. Molnar, M. Eisenbauer, A. Czirok, B. Dekan,et al. (2013) Cell migration or cytokinesis and proliferation? - revisiting the "go or grow" hypothesis in cancer cells in vitro. Exp Cell Res 319:3094–3103CrossRef Garay, T., E. Juhasz, E. Molnar, M. Eisenbauer, A. Czirok, B. Dekan,et al. (2013) Cell migration or cytokinesis and proliferation? - revisiting the "go or grow" hypothesis in cancer cells in vitro. Exp Cell Res 319:3094–3103CrossRef
19.
Zurück zum Zitat Wellinghausen N, Kirchner H, Rink L (1997) The immunobiology of zinc. Immunol Today 18:523–524CrossRef Wellinghausen N, Kirchner H, Rink L (1997) The immunobiology of zinc. Immunol Today 18:523–524CrossRef
20.
Zurück zum Zitat Franklin RB, Costello LC (2009) The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem 106:750–757CrossRef Franklin RB, Costello LC (2009) The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem 106:750–757CrossRef
21.
Zurück zum Zitat Kim I, Kim CH, Seo GH, Kim HS, Lee J, Kim DG, Ahn YS (2008) Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport 19:1065–1068 Kim I, Kim CH, Seo GH, Kim HS, Lee J, Kim DG, Ahn YS (2008) Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport 19:1065–1068
22.
Zurück zum Zitat Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D'Orazi G (2010) Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One 5:e15048CrossRef Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D'Orazi G (2010) Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One 5:e15048CrossRef
23.
Zurück zum Zitat Yuan Y, Hillind G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia inducible factor-a and von Hippel Lindau protein by direct binding to hypoxia inducible factor-a. J Biol Chem 278:15911–15916CrossRef Yuan Y, Hillind G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia inducible factor-a and von Hippel Lindau protein by direct binding to hypoxia inducible factor-a. J Biol Chem 278:15911–15916CrossRef
24.
Zurück zum Zitat Chun YS, Choi E, Yeo EJ, Lee HJ, Kim MS, Park JW (2001) A new HIF1 alpha variant induced by zinc ion suppresses HIF1-mediated hypoxic responses. J Cell Sci 114:4051–4061PubMed Chun YS, Choi E, Yeo EJ, Lee HJ, Kim MS, Park JW (2001) A new HIF1 alpha variant induced by zinc ion suppresses HIF1-mediated hypoxic responses. J Cell Sci 114:4051–4061PubMed
25.
Zurück zum Zitat Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G (2009) Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF1-alpha. PlosOne 4:e6819CrossRef Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G (2009) Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF1-alpha. PlosOne 4:e6819CrossRef
26.
Zurück zum Zitat Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46:1159–1169CrossRef Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46:1159–1169CrossRef
27.
Zurück zum Zitat Zbytek B, Peacock DL, Seagroves TN, Slominski A (2013) Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol 5:239–251CrossRef Zbytek B, Peacock DL, Seagroves TN, Slominski A (2013) Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol 5:239–251CrossRef
28.
Zurück zum Zitat Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H (2009) Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 34:e962–e964CrossRef Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H (2009) Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 34:e962–e964CrossRef
29.
Zurück zum Zitat Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O’Brien ET III, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY (2013) HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078–2093CrossRef Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O’Brien ET III, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY (2013) HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078–2093CrossRef
30.
Zurück zum Zitat Tátrai E, Bartal A, Gacs A, Paku S, Kenessey I, Garay T, Hegedűs B, Molnár E, Cserepes MT, Hegedűs Z, Kucsma N, Szakács G, Tóvári J (2017) Cell-type dependent HIF1α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget 8:44498–44510CrossRef Tátrai E, Bartal A, Gacs A, Paku S, Kenessey I, Garay T, Hegedűs B, Molnár E, Cserepes MT, Hegedűs Z, Kucsma N, Szakács G, Tóvári J (2017) Cell-type dependent HIF1α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget 8:44498–44510CrossRef
31.
Zurück zum Zitat Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525CrossRef Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525CrossRef
32.
Zurück zum Zitat Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz DE, Tambar UK, Gardner KH, Bruick RK (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9:271–276CrossRef Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz DE, Tambar UK, Gardner KH, Bruick RK (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9:271–276CrossRef
Metadaten
Titel
Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma
verfasst von
Z. Burián
A. Ladányi
T. Barbai
V. Piurkó
T. Garay
E. Rásó
József Tímár
Publikationsdatum
06.01.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-00573-1

Weitere Artikel der Ausgabe 2/2020

Pathology & Oncology Research 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.